Angle PLC Announces Parsortix Unlocks Opportunities for Drug Discovery

Rhea-AI Summary

ANGLE plc (AIM:AGL)(OTCQX:ANPCY) announces a breakthrough publication by researchers at the University of New Mexico, US, regarding the use of Parsortix system in pre-clinical model for gene expression profiling associated with melanoma brain metastasis. The study reveals the system's pivotal role in prescribing more targeted treatments based on patient needs, with a positive impact on therapeutic regime effectiveness.

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY

Harvested CTCs reveal gene expression profile associated with development and progression of brain metastasis in melanoma

Researchers suggest such profiling could prove to be "pivotal" to prescribing more targeted treatments in this setting

GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of breakthrough work by researchers at the University of New Mexico, US, into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that "… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient."

In this study, pre-clinical mouse models of melanoma brain metastasis were split into four treatment groups and two cancer drugs were tested individually and together vs. placebo. Blood samples were analysed using the Parsortix system to harvest CTCs. The authors found that using the two drugs together was the most effective therapeutic regime, reducing tumour burden, metastasis and CTC count.

This research provides further evidence of the capability of the Parsortix system to be used for the harvesting of CTCs for analysis in pre-clinical mouse models.

The global market for preclinical clinical research organisations exceeded a valuation of US$ 5 billion in 2022 and is expected to achieve a 7.5% CAGR over the next 10 years owing to increasing R&D expenditure on early-stage development combined with the growing number of drugs in preclinical development.

ANGLE Chief Executive Officer, Andrew Newland, commented:
"The use of CTC biomarkers in clinical trials is a rapidly growing field enabling longitudinal monitoring of transcriptomic and proteomic changes. ANGLE can provide pharma customers with a complete range of services to support preclinical and clinical drug development. This includes standardised and validated protocols for analysing CTCs including the established techniques of IF, dPCR and NGS, and the capability to deliver bespoke assays to identify drug targets and ascertain therapeutic efficacy."

This peer-reviewed journal article is published in the journal of Cancers and available at www.angleplc.com/publications.

For further information:

ANGLE plc	+44 (0) 1483 343434
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	+44 (0) 20 3207 7800
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	+44 (0) 203 727 1000 +1 (212) 850 5624

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix^® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.

ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix^® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for pharma.

Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: ANGLE plc

View the original press release on accesswire.com

FAQ

What is the breakthrough publication announced by ANGLE plc (AGL)(ANPCY)?

Researchers at the University of New Mexico, US, published a study regarding the use of Parsortix system in pre-clinical model for gene expression profiling associated with melanoma brain metastasis.

What is the role of the Parsortix system in prescribing more targeted treatments based on patient needs?

The study suggests that gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.

What was the conclusion of the study regarding the effectiveness of the therapeutic regime?

Using the two drugs together was found to be the most effective therapeutic regime, reducing tumour burden, metastasis, and CTC count.

Where can the peer-reviewed journal article be found?

The peer-reviewed journal article is published in the journal of Cancers and available at www.angleplc.com/publications.